Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 20, 2006

Actelion Purchases CoTherix for $420M

  • Actelion entered into a definitive agreement to acquire CoTherix. CoTherix currently markets Ventavis® (iloprost), an approved inhaled therapy for the treatment of pulmonary arterial hypertension in the U.S.

    The transaction has been approved unanimously by the boards of directors of both companies. Actelion will commence a cash tender offer of $13.50 per share of CoTherix, for a total acquisition price of approximately $420 million. This represents an approximate premium of 21% over CoTherix's closing price of $11.20 on November 17, 2006. The transaction is expected to be completed early in Q1 2007.

    In 2007, Actelion expects Ventavis sales to contribute more than $100 million  to product revenues. Actelion expects the transaction to be accretive to cash earnings in 2007 as a result of synergies.
    “We expect that the transaction will generate immediate substantial value, adding top-line revenue and bottom-line cash earnings by leveraging our existing marketing and sales infrastructure in the United States and expanding the reach of Ventavis" Jean-Paul Clozel, M.D., CEO of Actelion, commented.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »